These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Fuller TF; Feng S; Brennan TV; Tomlanovich S; Bostrom A; Freise CE Transplantation; 2004 Oct; 78(7):1030-5. PubMed ID: 15480170 [TBL] [Abstract][Full Text] [Related]
3. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. Chkhotua AB; Klein T; Shabtai E; Yussim A; Bar-Nathan N; Shaharabani E; Lustig S; Mor E Urology; 2003 Dec; 62(6):1002-6. PubMed ID: 14665344 [TBL] [Abstract][Full Text] [Related]
4. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial. Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925 [TBL] [Abstract][Full Text] [Related]
5. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759 [TBL] [Abstract][Full Text] [Related]
6. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome. Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376 [TBL] [Abstract][Full Text] [Related]
7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
8. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Haririan A; Morawski K; Sillix DH; El-Amm JM; Garnick J; West MS; Granger DK; Migdal SD; Gruber SA Transplantation; 2005 Mar; 79(6):716-21. PubMed ID: 15785379 [TBL] [Abstract][Full Text] [Related]
9. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785 [TBL] [Abstract][Full Text] [Related]
10. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888 [TBL] [Abstract][Full Text] [Related]
11. Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Campbell SB; Hothersall E; Preston J; Brown AM; Hawley CM; Wall D; Griffin AD; Isbel NM; Nicol DL; Johnson DW Transplantation; 2003 Nov; 76(10):1452-7. PubMed ID: 14657685 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of conventional immunosuppressive therapy in related and unrelated living renal transplantation. Thorban S; Schwarznau A; Hüser N; Stangl M Clin Transplant; 2006; 20(3):284-8. PubMed ID: 16824142 [TBL] [Abstract][Full Text] [Related]